Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
Article
en En
| IMSEAR
| ID: sea-89372
Numerous investigators have shown that the glycoprotein IIb/IIIa integrin mediates the final common pathway in platelet aggregation which has led to development of GP IIb/IIIa receptor antagonists. This article reviews the current status of GP IIb/IIIa receptor blockade in the management of coronary artery disease, examining the results of pivotal clinical trials.
Texto completo:
1
Índice:
IMSEAR
Asunto principal:
Humanos
/
Fragmentos Fab de Inmunoglobulinas
/
Inhibidores de Agregación Plaquetaria
/
Terapia Trombolítica
/
Complejo GPIIb-IIIa de Glicoproteína Plaquetaria
/
Enfermedad Coronaria
/
Anticuerpos Monoclonales
Idioma:
En
Año:
2000
Tipo del documento:
Article